Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Gilead Announces SVR12 Rates from Four Phase 3 Studies Evaluating a Once-Daily, Fixed-Dose Combination of Sofosbuvir (SOF) and Velpatasvir (VEL) (GS-5816) for the Treatment of All Six Hepatitis C Genotypes

If Approved, SOF/VEL Would be the First All-Oral Pan-Genotypic Single Tablet Regimen for Chronic HCV. U.S. NDA and European MAA Submissions Planned for Q4. 2015.

Published
21 September 2015
From
Gilead press release
Achillion Reports 100% SVR12 From Second Cohort of Patients in the Previously-Completed Six Week Phase 2 Trial Evaluating Odalasvir (ACH-3102) and Sofosbuvir for Genotype 1 HCV ("Proxy Study")

100% SVR12 reported for all patients treated for six- (n=18) or eight-weeks (n=12). Odalasvir (ACH-3102) is the subject of an exclusive, worldwide development and commercialization license granted to Janssen

Published
18 September 2015
From
Achillion press release
Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission

Daklinza in combination with sofosbuvir is the first 12-week all-oral therapy for genotype 3 patients without cirrhosis in Europe.

Published
15 September 2015
From
Bristol-Myers Squibb press release
Ongoing Real World Study Reports High Sustained Viral Response Rates with VIEKIRAX® + EXVIERA® in Genotype 1 Hepatitis C Patients

Interim results from the independent AMBER study demonstrated 98 percent (n=39/40) SVR(12) rate in patients who completed a 12- or 24-week treatment regimen and 12 weeks follow-up.

Published
14 September 2015
From
AbbVie press release
Hepatitis C patients in England denied lifesaving liver drug

Health experts concerned about decision not to extend Daklinza treatment to patients with genotype 3 strain of virus.

Published
18 August 2015
From
The Observer
Medicines Patent Pool At 5 Years: Promises Kept, Changes Ahead – An Interview With Greg Perry

The Medicines Patent Pool in Geneva is celebrating five years of existence this month. MPP Executive Director Greg Perry sat down with Intellectual Property Watch Catherine Saez to describe progress made since its inception, the success of its licensing agreement model, and plans for the future, including a possible extension to other diseases such as tuberculosis and hepatitis C.

Published
04 August 2015
From
Intellectual Property Watch
FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

The FDA has approved BMS's Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

Published
27 July 2015
From
AIDSMeds
FDA approves Technivie for treatment of chronic hepatitis C genotype 4

The U.S. Food and Drug Administration today approved Technivie (ombitasvir, paritaprevir and ritonavir) for use in combination with ribavirin for the treatment of hepatitis C virus (HCV) genotype 4 infections in patients without scarring and poor liver function (cirrhosis).

Published
27 July 2015
From
FDA
TAG Pipeline Report

2015 report on the pipeline for new HIV, HCV and TB drugs.

Published
17 July 2015
From
TAG
Gilead pills priced at $1,000 a day are found cost-effective

Health insurers that have been reluctant to cover hepatitis C drugs with list prices of $1,000 a daily dose will face more pressure after a report concluding the medications are “cost-effective” given their benefits.

Published
14 July 2015
From
Bloomberg

Filter by country